Half-year results from Ramsay Health Care Limited (ASX:RHC), Mesoblast Ltd (ASX:MSB, NASDAQ:MESO) and Sigma Healthcare highlight the different operating dynamics currently shaping large-cap healthcare in Australia — from hospital margin recovery to pharmacy integration and early-stage commercial biotech revenue.
While all three companies reported growth or improvement across key metrics, the market response has diverged, reflecting how investors are weighing earnings visibility against structural transition and commercial execution.
Ramsay Health Care — profit recovery takes centre stage
Ramsay released its half-year result yesterday, delivering a clear return to profitability.
For the six months to December 31, the group reported statutory NPAT (after non-controlling interests) of $160.7 million, reversing a $104.9 million loss in the prior corresponding period. On an underlying basis, NPAT (after NCI) rose 8.1% to $171.7 million, while underlying EBIT increased 7.3% to $536.7 million.
Revenue and other income (less interest income) climbed 9.3% to $9.38 billion. The board declared a fully franked interim dividend of 42.5 cents per share, up 6.3%, and reduced full-year capex guidance to $755 million–795 million.
Management pointed to improving admissions growth in Australia (excluding Peel Health Campus), higher acuity and private health insurance indexation running ahead of labour cost growth. EBIT margins excluding Joondalup improved by 40 basis points.
Shares surged more than 10% following yesterday’s release and rose another 2% on Friday, remain up more than 12% over the past week and nearly 20% over the past month.
Sigma Healthcare — earnings growth alongside integration
Sigma also reported yesterday, posting strong half-year growth as integration of the Chemist Warehouse transaction progresses.
Revenue reached $5.5 billion, up 14.9% on a pro-forma basis. Normalised EBIT rose 18.7% to $582.9 million, while normalised NPAT increased 19.2% to $392.0 million. A 2.0 cent fully franked interim dividend was declared.
Australian Chemist Warehouse branded store sales grew 17.2% to $5.1 billion, with like-for-like growth of 15.0%. Sigma said it delivered $13.0 million in early synergies during the half, working towards a $100 million per annum target by FY29, and reduced net debt by $117.1 million to $635.1 million.
The stock initially jumped more than 6% after the announcement but had eased by Friday afternoon, down 3% on the day as investors continue to assess integration progress and underlying earnings trends.
Mesoblast — commercial revenue accelerates
Mesoblast’s half-year update, released today, marked a significant commercial milestone following the US launch of Ryoncil.
Total revenue rose to US$51.3 million, compared with US$3.2 million a year earlier. Ryoncil generated US$57.0 million in gross sales and US$48.7 million in net revenue after gross-to-net adjustments, delivering gross profit (excluding amortisation) of US$44.2 million.
The company reported a net loss of US$40.2 million and net operating cash spend of US$30.3 million, finishing the period with US$130.0 million in cash and access to a US$125.0 million credit facility. It guided to FY26 Ryoncil net revenue of US$110 million–120 million, with 49 transplant centres onboarded and a target of 64.
Shares fell by more than 7% on Friday and remain down more than 16% over the past month, as the market weighs revenue momentum against the path to sustained profitability.
Sector snapshot
Taken together, the three results illustrate the breadth of earnings profiles within healthcare: an established hospital operator demonstrating margin recovery, an integrated retail-pharmacy group delivering scale and synergies, and a commercial-stage biotech moving from approval to revenue.
The differences in share price reaction suggest investors remain particularly focused on the clarity and durability of earnings in the current reporting cycle.